Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | FPR1 | P21462 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829715 | 1.00 | CNR1 (0.50) | CNR1HRH3EPHX2KDM1APTPN11 | |
| SCHEMBL2826056 | 0.83 | CNR1 (0.51) | CNR1HRH3EPHX2KDM1APTPN11 | |
| SCHEMBL2830728 | 0.83 | HRH3 (0.56) | CNR1HRH3EPHX2KDM1APTPN11 | |
| SCHEMBL2827804 | 0.81 | MEN1 (0.52) | HRH3EPHX2KDM4EMAPT | |
| SCHEMBL2829128 | 0.81 | CNR1 (0.48) | CNR1HRH3EPHX2KDM1AFPR1 | |
| SCHEMBL2825707 | 0.79 | HRH3 (0.55) | HRH3PTPN11HDAC1KDM4E | |
| SCHEMBL2830938 | 0.79 | HRH3 (0.50) | HRH3PTPN11HDAC1KDM4EMAPT | |
| Cyclohexane SCHEMBL2824747 | 0.79 | HRH3 (0.50) | HRH3PTPN11HDAC1KDM4EMAPT | |
| Cyclopropane SCHEMBL2826295 | 0.79 | HRH3 (0.50) | HRH3PTPN11HDAC1KDM4EMAPT | |
| Cyclopentane SCHEMBL2825703 | 0.79 | HRH3 (0.50) | HRH3PTPN11HDAC1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | claimed |
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-7528135-B2 | Pyridine derivatives as H3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | HRH3, HRH4, HRH2 | CNR1 20/4885HRH3 1/4885EPHX2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.